Stay updated on Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:10.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the effectiveness and safety comparison of nivolumab and bevacizumab in patients with recurrent glioblastoma, as well as the evaluation of nivolumab with or without ipilimumab in different lines of therapy for glioblastoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:11.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying requirements such as histologically confirmed Grade IV malignant glioma and previous treatment with radiotherapy and temozolomide. This change provides more specific information for researchers looking to enroll participants in the study.
    Difference
    11%
    Check dated 2024-05-22T20:59:50.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:44:06.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Bevacizumab in Glioblastoma Clinical Trial page.